Business Context and Reporting Period
Company: Impact BioMedical, Inc. (NYSE American: IBO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2025
Business Overview: The Company discovers, patents, and licenses biopharmaceutical and wellness technologies, including oncology (Linebacker), metabolic health (Laetose), functional fragrances (3F), and antiviral blends (Equivir). It operates through several subsidiaries and relies on licensing agreements and strategic partnerships for commercialization. The Company completed an IPO in September 2024.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Total Costs and Expenses | $1,010,000 | $771,000 |
| Operating Loss | $(1,010,000) | $(771,000) |
| Net Loss | $(1,278,000) | $(998,000) |
| Net Loss Attributable to Common Stockholders | $(1,267,000) | $(962,000) |
| Loss Per Share (Basic & Diluted) | $(0.11) | $(0.10) |
| Cash and Cash Equivalents (End of Period) | $1,318,000 | $2,000 |
| Net Cash Used in Operating Activities | $(682,000) | $(482,000) |
| Total Assets | $20,051,000 | $20,290,000 |
| Total Liabilities | $13,241,000 | $13,053,000 |
| Related Party Note Payable | $9,141,000 | $8,878,000 |
Material Changes vs. Prior Period
- Expense Growth: Total costs and expenses increased 31% to $1.01 million. Significant drivers included a 66% increase in SG&A compensation due to added headcount, a 54% rise in professional fees, and a 3,733% surge in other operating expenses (primarily D&O insurance post-IPO).
- R&D Decline: Research and development expenses decreased 44% to $103,000, attributed to the completion of specific patent efforts in 2024 that did not continue into 2025.
- Inventory Build: Inventory increased from $0 to $489,000 following the acquisition of DSS PureAir assets, which included air filtration systems.
- Debt Increase: The related party note payable increased by $263,000 to $9.14 million due to accrued interest.
- Cash Position: Cash balances decreased by $681,000 during the quarter, driven by operating losses and working capital adjustments, despite a strong cash position at the start of the period following the 2024 IPO.
Outlook, Risks, and Unusual Items
- Going Concern: The filing states that substantial doubt exists regarding the Company's ability to continue as a going concern within one year due to recurring operating losses and negative cash flows. Management plans to address this through IP monetization and cost control.
- Acquisition Activity: In February 2025, the Company acquired assets from DSS PureAir, Inc. (a related party) for $1.15 million, paid via the issuance of 545,024 shares of common stock. This included inventory and intellectual property for the Celios air purification system.
- Related Party Transactions: The Company has significant exposure to DSS, Inc., including a revolving promissory note secured by Company assets and monthly pass-through administrative costs (approx. $26,000/month).
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, citing material weaknesses previously disclosed in the 2023 10-K that remained unremediated.
- Revenue Model: The Company has not generated significant revenue from operations. Future revenue is contingent on milestone and royalty payments from licensing partners (e.g., ProPhase Laboratories, Chemia).
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $1.3 million cash balance against the $682,000 quarterly burn rate and the $9.1 million related party debt obligation.
- Related Party Note Terms: Review the specific terms of the DSS Revolving Promissory Note, including the equity conversion features and the impact of the fair value adjustments on earnings.
- Internal Control Remediation: Assess the timeline and progress of remediation steps for the material weaknesses in internal controls over financial reporting.
- Commercialization Progress: Confirm the status of licensing agreements with ProPhase Laboratories and Chemia to determine the likelihood of future royalty or milestone revenue.
- Inventory Valuation: Evaluate the marketability and net realizable value of the $489,000 inventory acquired from DSS PureAir.